Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:35:34 EST Sun 16 Nov 2025
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q1.00.65·1.198.31.16+0.010.9819.38761,4041.10  1.20  1.106.89  0.556219:40:43Nov 1215 min RT 2¢

Recent Trades - Last 10 of 1404
Time ETExPriceChangeVolume
19:40:43Q1.14-0.012,265
19:33:59Q1.160.017
19:09:52Q1.160.012
18:42:30Q1.1405-0.00951
18:30:17Q1.17990.02991
18:03:27Q1.180.0311
18:00:34Q1.14-0.01700
17:46:05Q1.1419-0.00811
17:27:38Q1.14-0.011
17:21:59Q1.14-0.011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-12 16:01U:IBIONews ReleaseiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-10-30 07:00U:IBIONews ReleaseiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
2025-10-23 07:00U:IBIONews ReleaseiBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-21 07:00U:IBIONews ReleaseiBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek(TM) and PEGS Europe 2025
2025-09-05 07:30U:IBIONews ReleaseiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
2025-08-25 07:00U:IBIONews ReleaseiBio Announces Closing of $50 Million Public Offering
2025-08-19 08:01U:IBIONews ReleaseiBio Announces Pricing of $50 Million Public Offering
2025-08-18 16:01U:IBIONews ReleaseiBio Announces Proposed Public Offering
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
2025-06-23 16:15U:IBIONews ReleaseiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
2025-06-16 07:00U:IBIONews ReleaseiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction
2025-04-22 08:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
2025-04-07 07:00U:IBIONews ReleaseiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
2025-02-19 16:05U:IBIONews ReleaseiBio to Begin Trading on the Nasdaq Stock Exchange
2025-02-10 16:05U:IBIONews ReleaseiBio Reports Fiscal Second Quarter 2025 Financial Results
2025-01-13 07:00U:IBIONews ReleaseiBio Announces New Investments from Board Members and Officers
2025-01-07 07:00U:IBIONews ReleaseiBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio